Clinical trials: Immunocompromised Patients
Actinic Keratoses
Effects of Topical Diclofenac on Tumor Metabolism
The rationale of this study is to investigate the effects of topical diclofenac on tumor metabolism in the treatment of actinic keratoses in immunocompetent and immunocompromised patients.
- Trial name
- NCT01935531
- Testing
- 3% diclofenac in 2.5% hyaluronic acid gel
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University Hospital Regensburg
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
Molluscum Contagiosum
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
Patients at least 18 years of age will be enrolled in the study to assess the efficacy and tolerability of Picato gel in the treatment of molluscum contagiosum.
- Trial name
- NCT03336372
- Testing
- Picato
- Where
- United States
- Sponsor
- Center for Clinical Studies, Texas
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Aspergillosis
Voriconazole For Chronic Bronchopulmonary Aspergillosis
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e.
- Trial name
- NCT00159822
- Testing
- Voriconazole
- Where
- 18 sites in France
- Volunteers
- 48 people
- Sponsor
- Pfizer
Severely Immunocompromised HIV Patients
Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients
The current available antiretroviral (ARV) agents make possible a successful treatment of virtually all HIV-infected patients, but some problems related to early mortality are still of concern, mainly in resources-limited…
- Trial name
- IDEA (NCT01837277)
- Testing
- Dolutegravir 50 mg, Efavirenz-based regimens
- Where
- 3 sites in Brazil
- Volunteers
- 186 people
- Sponsor
- Fundação Bahiana de Infectologia
Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ventilator-associated or…
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired, Immunodeficiency
- Trial name
- RESPIRE (NCT05405491)
- Testing
- PCR based strategy, Standard care
- Where
- France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Lille
Invasive Aspergillosis
Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study
Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy.
- Trial name
- ARPO (NCT06069505)
- Testing
- Aspergillus PCR
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Bart Rijnders
HIV Seropositivity, Immunodeficiency
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional…
- Conditions
- HIV Seropositivity, Immunodeficiency, Vaccination Reaction, Covid19
- Trial name
- NCT05672654
- Testing
- Blood draw
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE
Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant
A prospective, multisite study to evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® vaccination in pediatric patients 6-24 months of age who are being considered and/or evaluated for any solid organ transplant…
- Conditions
- RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
- Trial name
- ProQuad® (NCT02687763)
- Testing
- ProQuad
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
COVID-19, Immunocompromised Host
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns
- Trial name
- PRECOVIM (NCT05216588)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Cytomegalovirus Viraemia
Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems.
- Trial name
- ID-MAGIC (NCT06574789)
- Testing
- Standard dosing of IV ganciclovir, Personalised dosing of IV ganciclovir
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 232 people
- Sponsor
- Murdoch Childrens Research Institute
Immunocompromised, Hematologic Malignancy
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy
Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung infection. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula).
- Conditions
- Immunocompromised, Hematologic Malignancy, Post Hematopoietic Stem Cell Transplant, Hypoxia
- Trial name
- NCT03168815
- Testing
- High Flow Nasal Cannula or Low Flow Nasal Cannula
- Where
- Canada
- Volunteers
- 98 people
- Sponsor
- Mount Sinai Hospital, Canada
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Invasive Aspergillosis, Other Fungal Infections
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by…
- Trial name
- NCT00158730
- Testing
- AmBisome
- Volunteers
- 800 people
- Sponsor
- Gilead Sciences
HBV
HBV Reactivation in Immunocompromised Patients (REANT STUDY)
Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy.
- Trial name
- NCT07529171
- Testing
- Antiviral
- Where
- 16 sites in Turkey (Türkiye)
- Volunteers
- 490 people
- Sponsor
- Yaşar Bayındır, MD
Immunocompromised Patients
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
Herpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status.
- Trial name
- AID4FRAIL_RZV (NCT07321808)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Infection, Infections, Bacterial
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection…
- Conditions
- Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
- Trial name
- OPTIMUM (NCT07110636)
- Testing
- Metagenomic plasma-based test for agnostic pathogen detection
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Karius, Inc.
Acute Respiratory Failure, Immunosuppression
HFNC Alone or Associated With NIV for Immunocompromised Patients Admitted to ICU for Acute Respiratory Failure
Acute respiratory failure is the leading cause of ICU admission of immunocompromized patients. In this subgroup of patients, the need for intubation and invasive mechanical ventilation occurs in about 50% of cases and is…
- Trial name
- FLORALI-IM (NCT02978300)
- Testing
- NIV/HFNC, HFNC
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Poitiers University Hospital